Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities

Toxicological Sciences

Volumn 97, Issue 1, 2007, Pages 205-213

  Ong, Michie M K ^a   Latchoumycandane, Calivarathan ^a   Boelsterli, Urs A ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Determinants of susceptibility; Drug induced liver injury (DILI); Hepatotoxicity; Idiosyncratic drug toxicity; Mitochondria; Oxidative stress; Superoxide dismutase

Indexed keywords

ACONITATE HYDRATASE; ALANINE AMINOTRANSFERASE; CARBONYL DERIVATIVE; FLUORESCENT DYE; GLUTATHIONE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; HETEROZYGOSITY; LIVER CELL; LIVER INJURY; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER TOXICITY; LONG TERM EXPOSURE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; SILENT GENE; SINGLE DRUG DOSE; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GENETICS; LIVER; LIVER DISEASE; METABOLISM; NECROSIS; PATHOLOGY; PROTEIN CARBONYLATION; TIME; TRANSGENIC MOUSE;

ANIMALIA; MUS; RODENTIA;

ACONITATE HYDRATASE; ANIMALS; CHROMANS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; GLUTATHIONE; HYPOGLYCEMIC AGENTS; LIVER; LIVER DISEASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA, LIVER; MITOCHONDRIAL DISEASES; NECROSIS; OXIDATIVE STRESS; PROTEIN CARBONYLATION; SUPEROXIDE DISMUTASE; SUPEROXIDES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 34347250517     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfl180     Document Type: Article

References (40)

1. Boelsterli, U. A. (2003). Idiosyncratic drug hepatotoxicity revisited: New insights from mechanistic toxicology. Toxicol. Mech. Methods 13, 3-20.
2. Chinnery, P. F., Johnson, M. A., Wardell, T. M., Singh-Kler, R., Hayes, C., Brown, D. T., Taylor, R. W., Bindoff, L. A., and Turnbull, D. M. (2000). The epidemiology of pathogenic mitochondrial DNA mutations. Ann. Neurol. 48, 188-193.
3. Chojkier, M. (2005). Troglitazone and liver injury: In search of answers. Hepatology 41, 237-246.
4. DiMauro, S., and Schon, E. A. (2003). Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348, 2656-2668.
5. Estornell, E., Fato, R., Pallotti, F., and Lenaz, G. (1993). Assay conditions for the mitochondrial NADH:cOenzyme Q oxidoreductase. FEBS Lett. 332, 127-131.
6. Fernandez-Checa, J. C., and Kaplowitz, N. (2005). Hepatic mitochondrial glutathione: Transport and role in disease and toxicity. Toxicol. Appl. Pharmacol. 204, 263-273.
7. Graham, D. J., Green, L., Senior, J. R., and Nourjah, P. (2002). Troglitazone-induced liver failure: A case study. Am. J. Med. 114, 299-306.
8. Haskins, J. R., Rowse, P., Rahbari, R., and de la Iglesia, F. A. (2001). Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol. 75, 425-438.
9. He, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J., and Woolf, T. F. (2004). Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32, 639-646.
10. He, K., Woolf, T. F., Kindt, E. K., Fielder, A. E., and Talaat, R. E. (2001). Troglitazone quinone formation catalyzed by human and rat CYP3A: An atypical CYP oxidation reaction. Biochem. Pharmacol. 62, 191-198.
11. Herman, J. R., Dethloff, L. A., McGuire, E. J., Parker, R. F., Walsh, K. M., Gough, A. W., Masuda, H., and De la Iglesia, F. A. (2002). Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol. Sci. 68, 226-236.
12. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie, T. A. (2001). Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70.
13. Kirman, C. R., Sweeney, L. M., Meek, M. E., and Gargas, M. L. (2005). Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol. 38, 345-367.
14. Kokoszka, J. E., Coskun, P., Esposito, L., and Wallace, D. C. (2001). Increased mitochondrial oxidative stress in the Sod2+/-mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc. Natl. Acad. Sci. U.S.A. 98, 2278-2283.
15. Lebovitz, R. M., Zhang, H., Vogel, H., Cartwright, J., Dionne, L., Lu, N., Huang, S., and Matzuk, M. M. (1996). Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 93, 9782-9787.
16. Li, Q., Sato, E. F., Kira, Y., Nishikawa, M., Utsumi, K., and Inoue, M. (2006). A possible cooperation of SOD1 and cytochrome c in mitochondria-dependent apoptosis. Free Radic. Biol. Med. 40, 173-181.
17. -/+ mice. Free Radic. Biol. Med. 36, 542-554.
18. Loi, C. M., Young, M., Randinitis, E., Vassos, A., and Koup, J. R. (1999). Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 37, 91-104.
19. Masubuchi, Y., Kano, S., and Horie, T. (2006). Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222, 233-239.
20. Melov, S., Coskun, P., Patel, M., Tuinstra, R., Cottrell, B., Jun, A. S., Zastawny, T. H., Dizdaroglu, M., Goodman, S. I., Huang, T. T., et al. (1999). Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc. Natl. Acad. Sci. U.S.A. 96, 846-851.
21. Narayanan, P. K., Hart, T., Elcock, F., Zhang, C., Hahn, L., McFarland, D., Schwartz, L., Morgan, D. G., and Bugelski, P. (2003). Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry A 52, 28-35.
22. +/-mice. Free Radic. Biol. Med. 40 420-429.
23. Pessayre, D., Fromenty, B., Mansouri, A., and Berson, A. (2003). Hepatotoxicity due to mitochondrial injury. In Drug-Induced Liver Disease (N. Kaplowitz and L. DeLeve, Eds.), pp. 55-83. Marcel Dekker Inc, New York.
24. Prabhu, S., Fackett, A., Lloyd, S., McClellan, H. A., Terrell, C. M., Silber, P. M., and Li, A. P. (2002). Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem. Biol. Interact. 142, 83-97.
25. Pulkes, T., and Hanna, M. G. (2001). Human mitochondrial DNA diseases. Adv. Drug Deliv. Rev. 49, 27-43.
26. Rothwell, C., McGuire, E. J., Altrogge, D., Masuda, H., and De la Iglesia, F. A. (2002). Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J. Toxicol. Sci. 27, 35-47.
27. Shanske, S., and Wong, L. J. C. (2004). Molecular analysis for mitochondrial DNA disorders. Mitochondrion 4, 403-415.
28. Shishido, S., Koga, H., Harada, M., Kumemura, H., Hanada, S., Taniguchi, E., Kumashiro, R., Ohira, H., Sato, Y., Namba, M., et al. (2003). Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37, 136-147.
29. Smith, M. T. (2003). Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16, 679-687.
30. Suzuki, S., Hinokio, Y., Komatu, K., Ohtomo, M., Onoda, M., Hirai, S., Hirai, M., Hirai, A., Chiba, M., Kasuga, S., et al. (1999). Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res. Clin. Pract. 45, 161-168.
31. Tafazoli, S., Wright, J. S., and O'Brian, P. J. (2005). Prooxidant and antioxidant activity of vitamin E analogues and troglitazone. Chem. Res. Toxicol. 18, 1567-1574.
32. Tettey, J. N., Maggs, J. L., Rapeport, W. G., Pirmohamed, M., and Park, B. K. (2001). Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14, 965-974.
33. Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanam, P. K., Kurali, E., Hart, T. K., Thomas, H. C., and Schwartz, L. W. (2002). Effect of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69, 131-138.
34. Toyoda, Y., Tsuchida, A., Iwami, E., and Miwa, I. (2001). Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci. 68, 1867-1876.
35. Van Remmen, H., Ikeno, Y., Hamilton, M., Pahlavani, M., Wolf, N., Thorpe, S. R., Alderson, N. L., Baynes, J. W., Epstein, C. J., Huang, T. T., et al. (2003). Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genomics 16, 29-37.
36. Van Remmen, H., Salvador, C., Yang, H., Huang, T. T., Epstein, C. J., and Richardson, A. (1999). Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse. Arch. Biochem. Biophys. 363, 91-97.
37. Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., et al. (2003). A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73, 435-455.
38. Watkins, P. B., and Whitcomb, R. W. (1998). Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338, 916-917.
39. Williams, M. D., Van Remmen, H., Conrad, C. C., Huang, T. T., Epstein, C. J., and Richardson, A. (1998). Increased oxidative damage is correlated to mitochondrial function in heterozygous manganese dismutase knockout mice. J. Biol. Chem. 273, 28510-28515.
40. Yamamoto, Y., Nakajima, M., Yamazaki, H., and Yokoi, T. (2001). Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci. 70, 471-482.